Alkylated influenza vaccines
AssigneeSanofi Pasteur Biologics, LLC
InventorsBrooke S. Milner, Jonathan Haines, Steven L. Hauser, Janet Beebe Poli
Life of this patent
Estimating the term…
Abstract
The present invention provides, among other things, improved influenza vaccines based on hemagglutinins containing one or more alkylated cysteine residues. In particular, the present invention provides influenza vaccines containing hemagglutinins treated with an alkylating agent and methods of making the same. Inventive influenza vaccines provided by the present invention have a remarkable ability to retain potency as determined by Single Radial Immunodiffusion (SRID) assay upon storage.
Claims39
An influenza vaccine comprising a hemagglutinin containing one or more alkylated cysteine residues.
(canceled)
(canceled)
8-9. (canceled)
An influenza vaccine comprising a hemagglutinin treated with an alkylating agent.
12-13. (canceled)
A method of alkylating a hemagglutinin comprising a step of treating a purified hemagglutinin antigen or a hemagglutinin-containing viral particle with an alkylating agent.
22-25. (canceled)
A method of manufacturing an influenza vaccine comprising a step of treating a viral particle obtained from an influenza virus produced from an egg based or cell culture based production system with an alkylating agent.
(canceled)
A method of manufacturing an influenza vaccine, comprising
- harvesting influenza virus from an egg based or cell culture based production system;
- splitting the influenza virus;
- treating the split influenza virus with an alkylating agent;
- and
- inactivating the treated split influenza virus.
(canceled)
33-37. (canceled)
(canceled)
-53. (canceled)
55-57. (canceled)
60-67. (canceled)
Dependencies are inferred from the claim text.